目的 探究罗沙司他胶囊联合左卡尼汀注射液治疗肾性贫血的临床疗效。方法 选取2022年3月—2023年3月盐城市第三人民医院收治的80例肾性贫血患者，按照随机数表法将所有患者分为对照组和治疗组，每组各40例。对照组皮下注射重组人促红素注射液（CHO细胞），80～120 U/kg，2～3次/周，随后于血透结束后取0.9%氯化钠溶液10 mL与1.0 g左卡尼汀注射液混合后静脉注射，2～3次/周。治疗组口服罗沙司他胶囊，体质量40～60 kg者予以100 mg，体质量＞60 kg者予以120 mg，后续依据血红蛋白（Hb）水平调整剂量，3次/周。于血透结束后取0.9%氯化钠溶液10 mL与1.0 g左卡尼汀注射液混合后静脉注射，2～3次/周。两组均连续治疗12周。观察两组达标率，比较两组患者治疗前后贫血、铁代谢指标。结果 治疗后，两组的达标率分别为57.50%、80.00%，差异有统计学意义（P＜0.05）。治疗后，两组患者的Hb、红细胞压积（Hct）、红细胞计数（RBC）均升高，差异有统计学意义（P＜0.05）；且治疗组的Hb、Hct、RBC均高于对照组，差异有统计学意义（P＜0.05）。治疗后，两组患者的血清铁（SI）、不饱和铁结合力（UIBC）、血清铁饱和度（ISAT）均升高，不饱和铁结合力（UIBC）降低，差异有统计学意义（P＜0.05）；且治疗组的SI、TIBC、ISAT均高于对照组，UIBC低于对照组，差异有统计学意义（P＜0.05）。结论 罗沙司他胶囊联合左卡尼汀注射液可有效纠正肾性贫血患者贫血情况，促进铁的吸收和利用。

Objective To explore the effect of Roxadustat Capsules combined with Levocarnitine Injection in treatment of renal anemia. Methods Patients (80 cases) with renal anemia in Yancheng Third People’s Hospital from March 2022 to March 2023 were divided into control and treatment groups according to the random number table method, and each group had 40 cases. Patients in the control group were sc administered with Recombinant Human Erythropoietin Injection (CHO Cell), 80～120 U/kg, 2 — 3 times weekly. After hemodialysis, 1.0 g Levocarnitine Injection added into 0.9% sodium chloride solution 10 mL, 2 — 3 times weekly. Patients in the treatment group were po administered with Roxadustat Capsules, those with a body weight of 40 — 60 kg were given 100 mg, those with a body weight of > 60 kg were given 120 mg, and the dose was subsequently adjusted according to Hb level, 3 times weekly. After hemodialysis, 1.0 g Levocarnitine Injection added into 0.9% sodium chloride solution 10 mL, 2 — 3 times weekly. Patients in two groups were treated for 12 weeks. After treatment, compliance rates were evaluated, and the anemia indicators and the metabolism indexes in two groups were compared. Results After treatment, compliance rates of the two groups were 57.50% and 80.00%, respectively, with statistical significance (P < 0.05). After treatment, Hb, Hct, and RBC of two groups were increased, and the difference was statistically significant (P < 0.05). After treatment, Hb, Hct, and RBC in the treatment group were higher than those in the control group, and the difference was statistically significant (P < 0.05). After treatment, SI, TIBC, and ISAT in two groups were increased, while UIBC in two groups was decreased, with statistical significance (P < 0.05). After treatment, SI, TIBC, and ISAT in the treatment group were higher than those in the control group, but UIBC in the treatment group was lower than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion Roxadustat Capsules combined with Levocarnitine Injection can effectively correct anemia in patients with renal anemia and promote iron absorption and utilization.

R973